Literature DB >> 22021068

Serum inhibits the immunosuppressive function of myeloid-derived suppressor cells isolated from 4T1 tumor-bearing mice.

Melisa J Hamilton1, Judit P Banáth, Vivian Lam, Nancy E Lepard, Gerald Krystal, Kevin L Bennewith.   

Abstract

As more groups investigate the role of myeloid-derived suppressor cells (MDSCs) in promoting the growth of primary tumors and distant tumor metastases, it is imperative to ensure the accurate detection and quantification of MDSC immunosuppression ex vivo. MDSCs are defined by their ability to suppress immune responses. Although different in vitro culture conditions have been used to study MDSCs, the effect of different culture conditions on MDSC immunosuppression is unknown. We therefore isolated MDSCs from the lungs and spleens of 4T1 murine mammary tumor-bearing mice and assayed MDSC-mediated suppression of T cell responses under different culture conditions. We found that 4T1-induced MDSCs effectively suppressed T cell proliferation under serum-free conditions, but not when fetal calf serum (FCS) was present. FCS neither altered the immunosuppressive activities of other myeloid cell types (i.e., peritoneal or tumor-associated macrophages) nor modified the susceptibility of T cells to myeloid cell-mediated suppression, but instead acted directly on 4T1-induced MDSCs to significantly reduce their immunosuppressive function. Importantly, we found that bovine serum albumin was a major contributor to the antagonistic effects of FCS on 4T1-induced MDSC immunosuppression by inhibiting reactive oxygen species production from MDSCs. This work reveals that in vitro culture conditions influence the immunosuppressive properties of MDSCs and highlights the importance of testing different culture conditions on MDSC phenotype to ensure that MDSC immunosuppression is not being masked. These data have important implications for the accurate detection and identification of MDSCs, as well as for determining the influence of MDSC-mediated immunosuppression on primary and metastatic tumor growth.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22021068     DOI: 10.1007/s00262-011-1125-0

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  7 in total

1.  Aerobic Glycolysis Controls Myeloid-Derived Suppressor Cells and Tumor Immunity via a Specific CEBPB Isoform in Triple-Negative Breast Cancer.

Authors:  Wei Li; Takashi Tanikawa; Ilona Kryczek; Houjun Xia; Gaopeng Li; Ke Wu; Shuang Wei; Lili Zhao; Linda Vatan; Bo Wen; Pan Shu; Duxin Sun; Celina Kleer; Max Wicha; Michael Sabel; Kaixiong Tao; Guobin Wang; Weiping Zou
Journal:  Cell Metab       Date:  2018-05-24       Impact factor: 27.287

2.  In vitro effect of human serum and fetal calf serum on CD4+ T cells proliferation in response to myelin oligodendrocyte glycoprotein (MOG) in correlation with RBP/TTR ratio in multiple sclerotic patients.

Authors:  Niyaz Mohammadzadeh Honarvar; Mohammad Hossein Harrirchian; Fariba Koohdani; Fereydoon Siassi; Sima Jafari Rad; Mina Abdolahi; Sama Bitarafan; Eisa Salehi; Mohammad Ali Sahraian; Mohammad Reza Eshraghian; Ali Akbar Saboor-Yarghi
Journal:  J Mol Neurosci       Date:  2013-04-06       Impact factor: 3.444

3.  Suppression of vaccine immunity by inflammatory monocytes.

Authors:  Leah A Mitchell; Angela J Henderson; Steven W Dow
Journal:  J Immunol       Date:  2012-11-07       Impact factor: 5.422

4.  SHIP represses lung inflammation and inhibits mammary tumor metastasis in BALB/c mice.

Authors:  Melisa J Hamilton; Elizabeth C Halvorsen; Nancy E LePard; Momir Bosiljcic; Victor W Ho; Vivian Lam; Judit Banáth; Kevin L Bennewith; Gerald Krystal
Journal:  Oncotarget       Date:  2016-01-26

5.  Off-Target and Tumor-Specific Accumulation of Monocytes, Macrophages and Myeloid-Derived Suppressor Cells after Systemic Injection.

Authors:  Francis Combes; Séan Mc Cafferty; Evelyne Meyer; Niek N Sanders
Journal:  Neoplasia       Date:  2018-07-18       Impact factor: 5.715

6.  Targeting myeloid-derived suppressor cells in combination with primary mammary tumor resection reduces metastatic growth in the lungs.

Authors:  Momir Bosiljcic; Rachel A Cederberg; Melisa J Hamilton; Nancy E LePard; Bryant T Harbourne; Jenna L Collier; Elizabeth C Halvorsen; Rocky Shi; S Elizabeth Franks; Ada Y Kim; Judit P Banáth; Mark Hamer; Fabio M Rossi; Kevin L Bennewith
Journal:  Breast Cancer Res       Date:  2019-09-05       Impact factor: 6.466

7.  CAFs/tumor cells co-targeting DNA vaccine in combination with low-dose gemcitabine for the treatment of Panc02 murine pancreatic cancer.

Authors:  Fei Geng; Ling Dong; Xin Bao; Qianqian Guo; Jie Guo; Yi Zhou; Bin Yu; Hui Wu; Jiaxin Wu; Haihong Zhang; Xianghui Yu; Wei Kong
Journal:  Mol Ther Oncolytics       Date:  2022-07-31       Impact factor: 6.311

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.